Sanofi announced via press release that its drug frexalimab, directed against the ligand for the costimulatory receptor CD40 (CD40L), met its primary endpoint in patients with relapsing multiple ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...

Antibodies to the CD40 ligand have modulated the immune system in animal experiments and in human clinical trials. Assumptions about how these antibodies work are now reexamined. It is now 50 years ...

Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation BMS-986004, a single, one-time dose of 1,500 mg was ...

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist ...

Please provide your email address to receive an email when new articles are posted on . Disease activity in relapsing MS patients significantly fell following treatment with frexalimab, a novel second ...

Scientists from the Miller School of Medicine at the University of Miami have reported their recent work to develop small-molecule inhibitors of the CD40-CD40L (CD154) costimulatory protein-protein ...